Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2020

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2020-12-30: Form 6-K; Period of report 2020-12-30; Description ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK; Document a1114k.htm.
  • 2020-12-29: Form 6-K; Period of report 2020-12-29; Description LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P; Document a9403j.htm.
  • 2020-12-21: Form 6-K; Period of report 2020-12-21; Description TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST; Document a3346j.htm.
  • 2020-12-21: Form 6-K; Period of report 2020-12-21; Description UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS; Document a2445j.htm.
FiledFormPeriod of reportDescriptionDocument
2020-12-306-K2020-12-30ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UKa1114k.htm
2020-12-296-K2020-12-29LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND Pa9403j.htm
2020-12-216-K2020-12-21TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-STa3346j.htm
2020-12-216-K2020-12-21UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEASa2445j.htm
2020-12-176-K2020-12-17DIRECTOR/PDMR SHAREHOLDINGa0649j.htm
2020-12-166-K2020-12-16DIRECTOR/PDMR SHAREHOLDINGa9212i.htm
2020-12-156-K2020-12-15IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINIONa6756i.htm
2020-12-146-K2020-12-14TRASTUZUMAB DERUXTECAN POSITIVE CHMPa5168i.htm
2020-12-146-K2020-12-14TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPDa5163i.htm
2020-12-146-K2020-12-14ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INCa4622i.htm
2020-12-016-K2020-12-01BLOCK LISTING INTERIM REVIEWa1543h.htm
2020-12-016-K2020-12-01TOTAL VOTING RIGHTSa1534h.htm
2020-12-016-K2020-12-01CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPEa0730h.htm
2020-11-306-K2020-11-30FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILUREa8902g.htm
2020-11-236-K2020-11-23AZD1222 VACCINE EFFECTIVE AGAINST COVID-19a1393g.htm
2020-11-206-K2020-11-20IMFINZI NEW DOSING APPROVED IN THE USa9932f.htm
2020-11-106-K2020-11-10TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINTa8037e.htm
2020-11-096-K2020-11-09CALQUENCE APPROVED IN THE EU FOR CLLa6391e.htm
2020-11-066-K2020-11-06BRILINTA APPROVED IN THE US IN STROKEa4960e.htm
2020-11-056-K2020-11-05AZN: YEAR-TO-DATE AND Q3 2020 RESULTSa3158e.htm
2020-11-056-K2020-11-05FORXIGA APPROVED IN THE EU FOR HEART FAILUREa3141e.htm
2020-11-056-K2020-11-05LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB Fa3113e.htm
2020-11-056-K2020-11-05LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRATa3111e.htm
2020-11-026-K2020-11-02TOTAL VOTING RIGHTSa9472d.htm
2020-10-306-K2020-10-30ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIESa7408d.htm
2020-10-296-K2020-10-29DIRECTORATE CHANGEa5471d.htm
2020-10-286-K2020-10-28ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE METa4508d.htm
2020-10-286-K2020-10-28FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINAa4505d.htm
2020-10-206-K2020-10-20TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEWa6219c.htm
2020-10-196-K2020-10-19FORXIGA HF RECEIVES POSITIVE CHMP OPINIONa4479c.htm
2020-10-196-K2020-10-19TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINIONa4477c.htm
2020-10-136-K2020-10-13COVID-19 ANTIBODIES ADVANCE AND GET US FUNDINGa7051b.htm
2020-10-026-K2020-10-02FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASEa9316a.htm
2020-10-016-K2020-10-01TOTAL VOTING RIGHTSa8302a.htm
2020-09-256-K2020-09-25DIRECTORATE CHANGEa0739a.htm
2020-09-216-K2020-09-21LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC a5532z.htm
2020-09-216-K2020-09-21LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENTa5530z.htm
2020-09-216-K2020-09-21TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUVa5021z.htm
2020-09-106-K2020-09-10ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQa5949y.htm
2020-09-106-K2020-09-10FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE Ia5943y.htm
2020-09-016-K2020-09-01TOTAL VOTING RIGHTSa6718x.htm
2020-09-016-K2020-09-01IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCERa5813x.htm
2020-09-016-K2020-09-01FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATHa5586x.htm
2020-08-256-K2020-08-25PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PREa0200x.htm
2020-08-216-K2020-08-21IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG Ca8089w.htm
2020-08-186-K2020-08-18IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USEa4286w.htm
2020-08-066-K2020-08-06FORM 6-Kdp134017_6k.htm
2020-08-046-K2020-08-04ASTRAZENECA PRICES A $3BN BOND ISSUEa0073v.htm
2020-08-036-K2020-08-03TOTAL VOTING RIGHTSa9604u.htm
2020-07-316-K/A2020-06-306-K/Aa20-26252_16ka.htm
2020-07-306-K2020-07-30AZN: H1 2020 RESULTSa5880uv2.htm
2020-07-306-K2020-07-30TAGRISSO US BTD FOR EGFRM ADJUVANT LUNG CANCERa5855u.htm
2020-07-296-K2020-07-29BOARD COMMITTEE CHANGESa3896u.htm
2020-07-286-K2020-07-28FARXIGA DAPA-CKD TRIAL MET ALL ENDPOINTSa3045u.htm
2020-07-276-K2020-07-27IMFINZI RECOMMENDED FOR EU APPROVAL IN SCLCa1371u.htm
2020-07-276-K2020-07-27CALQUENCE RECEIVES POSITIVE CHMP OPINION FOR CLLa1373u.htm
2020-07-276-K2020-07-27ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGYa1369u.htm
2020-07-246-K2020-07-24BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPDa9975t.htm
2020-07-226-K2020-07-22HOLDING(S) IN COMPANYa7689t.htm
2020-07-226-K2020-07-22HOLDING(S) IN COMPANYa7687t.htm
2020-07-216-K2020-07-21HOLDING(S) IN COMPANYa5528t.htm
2020-07-216-K2020-07-21HOLDING(S) IN COMPANYa5526t.htm
2020-07-206-K2020-07-20COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN Pa5255t.htm
2020-07-166-K2020-07-16DIRECTOR DECLARATIONa1175t.htm
2020-07-096-K2020-07-09BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKEa5189s.htm
2020-07-086-K2020-07-08LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCERa3708s.htm
2020-07-016-K2020-07-01TOTAL VOTING RIGHTSa7381r.htm
2020-06-306-K2020-06-30DIRECTOR/PDMR SHAREHOLDINGa5568r.htm
2020-06-306-K2020-06-30SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE a4970r.htm
2020-06-176-K2020-06-17HOLDING(S) IN COMPANYa2558q.htm
2020-06-176-K2020-06-17HOLDING(S) IN COMPANYa2553q.htm
2020-06-156-K2020-06-15ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'Sa8921p.htm
2020-06-116-K2020-06-11EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUSa6018p.htm
2020-06-016-K2020-06-01TOTAL VOTING RIGHTSa5649o.htm
2020-06-016-K2020-06-01BLOCK LISTING INTERIM REVIEWa5617o.htm
2020-06-016-K2020-06-01LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANCa5013o.htm
2020-06-016-K2020-06-01BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKEa5007o.htm
2020-05-296-K2020-05-29ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2-a3961o1.htm
2020-05-296-K2020-05-29IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE a3956o2.htm
2020-05-296-K2020-05-29TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMa2952o.htm
2020-05-266-K2020-05-26DIRECTOR/PDMR SHAREHOLDINGa9151n.htm
2020-05-226-K2020-05-22ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCERa7390n.htm
2020-05-216-K2020-05-21ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST a5975n.htm
2020-05-206-K2020-05-20LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANTa4589.htm
2020-05-186-K2020-05-18ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCERa1713n.htm
2020-05-186-K2020-05-18BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPDa1711n.htm
2020-05-116-K2020-05-11ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE METa4552m.htm
2020-05-116-K2020-05-11ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COMa4546m.htm
2020-05-116-K2020-05-11LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB Fa4496m.htm
2020-05-066-K2020-05-06FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH Ha0848m.htm
2020-05-016-K2020-05-01TOTAL VOTING RIGHTSa6993l.htm
2020-04-296-K2020-04-29RESULT OF AGMa3758l.htm
2020-04-296-K2020-04-29AZN: FIRST-QUARTER 2020 RESULTSa2404l.htm
2020-04-246-K2020-04-24LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR Ba7693k.htm
2020-04-176-K2020-04-17CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETINGa0265k.htm
2020-04-146-K2020-04-14KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMATa4959j.htm
2020-04-146-K2020-04-14TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFICa4957j.htm
2020-04-026-K2020-04-02ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETEDa5496i.htm
2020-04-016-K2020-04-01TOTAL VOTING RIGHTSa4454i.htm
2020-03-316-K2020-03-31DIRECTOR/PDMR SHAREHOLDINGa1312i.htm
Advertisement